9MO: Amivantamab, lazertinib and bevacizumab in EGFR-mutant advanced NSCLC with acquired resistance to 3rd generation EGFR-TKI: Final results from the phase II ETOP AMAZE-lung trial
Publisher DOI
Date Issued
2025-03
Publication Type
Conference Item
Subject(s)
Language(s)
en
Author(s)
Soo, R.A. | |
Popat, S. | |
Dellaporta, T. | |
De Langen, A.J. | |
Nadal, E. | |
Gomez, P. Iranzo | |
Frueh, M. | |
Pérol, M. | |
Metro, G. | |
Gonzalez, M.A. Sala | |
Salamero, M. Cucurull | |
Addeo, A. | |
Roschitzki-Voser, H. | |
Ruepp, B. | |
Gasca, A. | |
Dafni, U. | |
Peters, S. | |
Stahel, R.A. |
Additional Credits
Journal
Journal of Thoracic Oncology
Publisher
Elsevier
ISSN
1556-0864
1556-1380
Access(Rights)
restricted